Status:
TERMINATED
Study of a Possible Respiratory Degradation Prognosis Caused by Biomarkers in Severe Forms of COVID-19 Pneumonia
Lead Sponsor:
Fondation Hôpital Saint-Joseph
Collaborating Sponsors:
Centre Hospitalier Victor Dupouy
Conditions:
Community-acquired Pneumonia
Covid19
Eligibility:
All Genders
18+ years
Brief Summary
Respiratory infection with the SARS-CoV2 virus is associated with a major risk of viral pneumonia that can lead to respiratory distress requiring resuscitation. In the most severe forms, it may requir...
Detailed Description
The mechanisms responsible for alveolar damage during viral pathologies, particularly Coronavirus, are very similar to those observed during acute respiratory distress syndromes in adults. Macrophages...
Eligibility Criteria
Inclusion
- Patient aged from 18 years old
- French-speaking patient
- Patient whose COVID-19 respiratory infection was confirmed by laboratory tests (either by a PCR and any other commercial or public health tests) or a scanner, that requires a hospitalization in a healthcare institution.
Exclusion
- Patient/ relative or proxy person opposed to the study participation
- Patient under guardianship or curators
- Patient deprived of liberty
- Patient under the safeguard of justice.
- Dying / Moribund patient
- Pregnant or breastfeeding woman
Key Trial Info
Start Date :
May 14 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 18 2021
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04505605
Start Date
May 14 2020
End Date
October 18 2021
Last Update
January 18 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier Victor Dupouy
Argenteuil, France, 95107
2
Groupe Hospitalier Paris Saint-Joseph
Paris, Île-de-France Region, France, 75014